May 7, 2020 / 10:20 PM / a month ago

BRIEF-Protagonist Therapeutics Reports First Quarter Financial Results And Provides Corporate Update

May 7 (Reuters) - Protagonist Therapeutics Inc:

* PROTAGONIST THERAPEUTICS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

* Q1 LOSS PER SHARE $0.72

* Q1 EARNINGS PER SHARE ESTIMATE $-0.69 — REFINITIV IBES DATA

* REVISED AND FOCUSED DEVELOPMENT PLANS NOW PROVIDE SUFFICIENT CAPITAL TO FUND OPERATIONS THROUGH MID-2022

* SELECTS POLYCYTHEMIA VERA INDICATION FOR PIVOTAL DEVELOPMENT OF PTG-300 BASED ON ROBUST CLINICAL RESPONSES

* DISCONTINUING CLINICAL DEVELOPMENT FOR PTG-300 IN BETA-THALASSEMIA AND MYELODYSPLASTIC SYNDROMES

* GUIDANCE HAS BEEN CURRENTLY SUSPENDED ON A TIMELINE FOR STUDY COMPLETION FOR PTG-200

* CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2020, WERE $117.5 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below